Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 330

1.

Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to their Plasmacytoma Presentation at Diagnosis

Çiftçiler R, Göker H, Demiroğlu H, Aksu S, Sayınalp N, Haznedaroğlu İC, Malkan ÜY, Büyükaşık Y, Özcebe O.

Turk J Haematol. 2019 Dec 13. doi: 10.4274/tjh.galenos.2019.2019.0061. [Epub ahead of print]

2.

The comparison of bone marrow kinetics between patients with acute myeloid leukemia and acute promyelocytic leukemia after induction chemotherapy.

Ciftciler R, Haznedaroglu IC, Ozcebe O, Aksu S, Sayınalp N, Goker H, Demiroglu H, Buyukasık Y.

Immunopharmacol Immunotoxicol. 2020 Feb;42(1):17-21. doi: 10.1080/08923973.2019.1692865. Epub 2019 Nov 19.

PMID:
31744339
3.

Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency

Aladağ E, Aksu S, Demiroğlu H, Sayınalp N, Göker H, Haznedaroğlu İC, Özcebe Oİ, Büyükaşık Y.

Turk J Med Sci. 2019 Oct 24;49(5):1560-1563. doi: 10.3906/sag-1907-67.

PMID:
31652037
4.

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors

Haznedaroğlu İC, Kuzu I, İlhan O.

Turk J Haematol. 2020 Feb 20;37(1):42-47. doi: 10.4274/tjh.galenos.2019.2019.0241. Epub 2019 Oct 15.

5.

The Factors Affecting Early Death in Newly Diagnosed APL Patients.

Ciftciler R, Haznedaroglu IC, Aksu S, Ozcebe O, Sayınalp N, Malkan UY, Buyukasık Y.

Open Med (Wars). 2019 Sep 12;14:647-652. doi: 10.1515/med-2019-0074. eCollection 2019.

6.

Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid Leukemia.

Ciftciler R, Demiroglu H, Haznedaroglu IC, Sayınalp N, Aksu S, Ozcebe O, Goker H, Aydın MS, Buyukasık Y.

Clin Lymphoma Myeloma Leuk. 2019 Nov;19(11):729-734. doi: 10.1016/j.clml.2019.08.007. Epub 2019 Aug 26.

PMID:
31540855
7.

Predictive factors for stem cell mobilization failure in multiple myeloma patients: A single center experience.

Goker H, Ciftciler R, Demiroglu H, Turgut M, Sayınalp N, Haznedaroglu IC, Okay M, Tekin F, Buyukasık Y.

Transfus Apher Sci. 2019 Aug 8:102595. doi: 10.1016/j.transci.2019.06.023. [Epub ahead of print]

PMID:
31492570
8.

The impact of early versus late platelet and neutrophil recovery after induction chemotherapy on survival outcomes of patients with acute myeloid leukemia

Çiftciler R, Haznedaroğlu İC, Sayınalp N, Özcebe O, Aksu S, Demiroğlu H, Göker H, Malkan ÜY, Büyükaşık Y.

Turk J Haematol. 2019 Sep 2. doi: 10.4274/tjh.galenos.2019.2019.0154. [Epub ahead of print]

9.

A unique case of complex variant translocation of t(6;9;22)(p22;q34;q11.2), der(19) in a newly diagnosed patient with chronic myeloid leukemia.

Ciftciler R, Saglam EA, Inanc A, Ozcebe O, Haznedaroglu IC.

Cancer Genet. 2019 Sep;237:78-81. doi: 10.1016/j.cancergen.2019.06.008. Epub 2019 Jun 13.

PMID:
31447069
10.

Ghosal hematodiaphyseal dysplasia with autoimmune anemia in two adult siblings.

Ciftciler R, Buyukasık Y, Saglam EA, Haznedaroglu IC.

Transfus Apher Sci. 2019 Aug;58(4):449-452. doi: 10.1016/j.transci.2019.04.027. Epub 2019 Jul 22.

PMID:
31395426
11.

Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma

Okay M, Büyükaşık Y, Demiroğlu H, Malkan ÜY, Çiftçiler R, Aladağ E, Aksu S, Haznedaroğlu İC, Sayınalp N, Özcebe Oİ, Göker H.

Turk J Med Sci. 2019 Aug 8;49(4):985-992. doi: 10.3906/sag-1809-36.

PMID:
31293116
12.

Indications and Outcomes of Splenectomy for Hematological Disorders.

Ciftciler R, Pasayeva A, Aksu S, Ozcebe O, Sayınalp N, Malkan UY, Buyukasık Y, Haznedaroglu IC.

Open Med (Wars). 2019 Jun 17;14:491-496. doi: 10.1515/med-2019-0054. eCollection 2019.

13.

Analysis of the Antiproliferative Effect of Ankaferd Hemostat on Caco-2 Colon Cancer Cells via LC/MS Shotgun Proteomics Approach.

Koçak E, Çelebier M, Haznedaroglu IC, Altınöz S.

Biomed Res Int. 2019 May 21;2019:5268031. doi: 10.1155/2019/5268031. eCollection 2019.

14.

The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia.

Ghasemi M, Okay M, Turk S, Naeemaee R, Guver E, Malkan UY, Aksu S, Sayinalp N, Haznedaroglu IC.

J Renin Angiotensin Aldosterone Syst. 2019 Apr-Jun;20(2):1470320319851310. doi: 10.1177/1470320319851310.

15.

Tumor Lysis Syndrome Due to Targeting of Hepatocellular Carcinoma Associated with Chronic Myelomonocytic Leukemia

Okay M, Çetik S, Haznedaroğlu İC.

Turk J Haematol. 2019 Aug 2;36(3):218-219. doi: 10.4274/tjh.galenos.2019.2019.0113. Epub 2019 May 9. No abstract available.

16.

The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases

Türk C, Okay M, Türk S, Temirci ES, Javad O, Aksu S, Sayınalp N, Haznedaroğlu İC.

Turk J Med Sci. 2019 Apr 18;49(2):661-674. doi: 10.3906/sag-1807-152.

PMID:
30997981
17.

The Antithrombin Effect of Ankaferd Hemostat (ABS) Is Related to the High Iron Content of the Medicine.

Okay M, Ozturk Y, Haznedaroglu IC.

Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029618824416. doi: 10.1177/1076029618824416. No abstract available.

18.

Branch retinal vein occlusion associated with platelet activation

Beyazyıldız E, Çıtırık M, Şimşek M, Beyazyıldız Ö, Haznedaroğlu İC.

Turk J Med Sci. 2019 Feb 11;49(1):283-287. doi: 10.3906/sag-1807-223.

PMID:
30761872
19.

Effects of Ankaferd Hemostat on Helicobacter pylori strains and antibiotic resistance

Çiftçiler R, Koluman A, Haznedaroğlu İC, Akar N.

Turk J Med Sci. 2019 Feb 11;49(1):347-355. doi: 10.3906/sag-1807-206.

PMID:
30761849
20.

Effects of Ankaferd Hemostat on red blood cell aggregation: a hemorheological study

Çiftçiler R, Aksu S, Dikmenoğlu Falkmarken N, Haznedaroğlu İC.

Turk J Med Sci. 2019 Feb 11;49(1):356-360. doi: 10.3906/sag-1808-60.

PMID:
30761848
21.

Current perspectives for the treatment of chronic myeloid leukemia

Aladağ E, Haznedaroğlu İC.

Turk J Med Sci. 2019 Feb 11;49(1):1-10. doi: 10.3906/sag-1810-81. Review.

PMID:
30761815
22.

Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study

Çiftçiler R, Göker H, Demiroğlu H, Aladağ E, Aksu S, Haznedaroğlu İC, Sayınalp N, Özcebe O, Tekin F, Büyükaşık Y.

Turk J Haematol. 2019 May 3;36(2):88-96. doi: 10.4274/tjh.galenos.2019.2018.0220. Epub 2019 Feb 5.

23.

Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia.

Ciftciler R, Demiroglu H, Buyukasık Y, Aladag E, Aksu S, Haznedaroglu IC, Sayınalp N, Ozcebe O, Malkan UY, Goker H.

Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):177-182. doi: 10.1016/j.clml.2018.11.016. Epub 2018 Dec 6.

PMID:
30616990
24.

Discontinuation of Imatinib Mesylate could Improve Renal Impairment in Chronic Myeloid Leukemia.

Malkan UY, Haznedaroglu IC.

Open Med (Wars). 2018 Dec 24;14:22-24. doi: 10.1515/med-2019-0004. eCollection 2019.

25.

Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patients.

Ciftciler R, Demiroglu H, Buyukasık Y, Okay M, Aksu S, Sayınalp N, Malkan UY, Haznedaroglu IC, Ozcebe O, Goker H.

Transfus Apher Sci. 2018 Dec;57(6):752-755. doi: 10.1016/j.transci.2018.09.013. Epub 2018 Sep 18.

PMID:
30249531
26.

On Being a “Physician Patient” with His Own Experimental Therapeutic Drug

Çiftçiler R, Haznedaroğlu İC.

Turk J Haematol. 2018 Nov 13;35(4):302-303. doi: 10.4274/tjh.2018.0254. Epub 2018 Jul 24. No abstract available.

27.

Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up.

Saydam G, Haznedaroglu IC, Kaynar L, Yavuz AS, Ali R, Guvenc B, Akay OM, Baslar Z, Ozbek U, Sonmez M, Aydin D, Pehlivan M, Undar B, Dagdas S, Ayyildiz O, Akin G, Dag IM, Ilhan O.

Hematology. 2018 Dec;23(10):771-777. doi: 10.1080/10245332.2018.1498167. Epub 2018 Jul 11.

PMID:
29996726
28.

Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Saydam G, Haznedaroglu IC, Kaynar L, Yavuz AS, Ali R, Guvenc B, Akay OM, Baslar Z, Ozbek U, Sonmez M, Aydin D, Pehlivan M, Undar B, Dagdas S, Ayyildiz O, Akkaynak DZ, Akin G, İlhan O.

Hematology. 2018 Feb 27:1-7. doi: 10.1080/10245332.2018.1444919. [Epub ahead of print] Retraction in: Hematology. 2018 Oct;23(9):720.

PMID:
29486663
29.

Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper.

Simsek C, Selek S, Koca M, Haznedaroglu IC.

SAGE Open Med. 2017 Jul 27;5:2050312117722569. doi: 10.1177/2050312117722569. eCollection 2017. Review.

30.

Lipotoxicity-Related Hematological Disorders in Obesity.

Haznedaroglu IC, Malkan UY.

Adv Exp Med Biol. 2017;960:469-487. doi: 10.1007/978-3-319-48382-5_20. Review.

PMID:
28585212
31.

Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines.

Turk S, Malkan UY, Ghasemi M, Hocaoglu H, Mutlu D, Gunes G, Aksu S, Haznedaroglu IC.

SAGE Open Med. 2017 Feb 10;5:2050312116689519. doi: 10.1177/2050312116689519. eCollection 2017.

32.

Clinical associations, biological risk factors and outcomes of cerebral venous sinus thrombosis.

Gunes HN, Cokal BG, Guler SK, Yoldas TK, Malkan UY, Demircan CS, Yon MI, Yoldas Z, Gunes G, Haznedaroglu IC.

J Int Med Res. 2016 Dec;44(6):1454-1461. doi: 10.1177/0300060516664807. Epub 2016 Nov 10.

33.

Peripheral FLT-3 ligand levels as a pathobiological parameter duringthe clinical course of acute myeloid leukemia.

Şahin M, Haznedaroğlu İC, Özbalcı D.

Turk J Med Sci. 2016 Dec 20;46(6):1889-1893. doi: 10.3906/sag-1504-87.

PMID:
28081344
34.

Ultrastructural analyses of the novel chimeric hemostatic agent generated via nanotechnology, ABS nanohemostat, at the renal tissue level.

Huri E, Dogantekin E, Hayran M, Malkan UY, Ergun M, Firat A, Beyazit Y, Ustun H, Kekilli M, Dadali M, Astarci M, Haznedaroglu IC.

Springerplus. 2016 Nov 8;5(1):1931. eCollection 2016.

35.

Sole Infrequent Karyotypic Aberration Trisomy 6 in a Patient with Acute Myeloid Leukemia and Breast Cancer in Remission.

Aydın MS, Bozkurt S, Güneş G, Malkan ÜY, Aslan T, Etgül S, Büyükaşık Y, Haznedaroğlu İC, Sayınalp N, Göker H, Demiroğlu H, Özcebe Oİ, Aksu S.

Turk J Haematol. 2017 Mar 1;34(1):103-104. doi: 10.4274/tjh.2016.0030. Epub 2016 Nov 22. No abstract available.

36.

Local bone marrow renin-angiotensin system in the genesis of leukemia and other malignancies.

Haznedaroglu IC, Malkan UY.

Eur Rev Med Pharmacol Sci. 2016 Oct;20(19):4089-4111. Review.

37.

Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Saydam G, Haznedaroglu IC, Kaynar L, Yavuz AS, Ali R, Guvenc B, Akay OM, Baslar Z, Ozbek U, Sonmez M, Aydin D, Pehlivan M, Undar B, Dagdas S, Ayyildiz O, Akkaynak DZ, Dag IM, Ilhan O.

Expert Opin Pharmacother. 2016 Oct;17(14):1851-8. doi: 10.1080/14656566.2016.1219338. Epub 2016 Aug 18.

PMID:
27501474
38.

Splenic artery embolization with Ankaferd blood stopper in a sheep model.

Koç O, Acar K, Özbek O, Güler İ, Sarıtaş K, Erdem TB, Solak Y, Toy H, Küçükapan A, Özbek S, Gaipov A, Haznedaroğlu İC.

Diagn Interv Radiol. 2016 Jul-Aug;22(4):354-7. doi: 10.5152/dir.2015.15382.

39.

Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma.

Ghasemi M, Alpsoy S, Türk S, Malkan ÜY, Atakan Ş, Haznedaroğlu İC, Güneş G, Gündüz M, Yılmaz B, Etgül S, Aydın S, Aslan T, Sayınalp N, Aksu S, Demiroğlu H, Özcebe OI, Büyükaşık Y, Göker H.

Turk J Haematol. 2016 Dec 1;33(4):286-292. doi: 10.4274/tjh.2015.0145. Epub 2016 Apr 18.

40.

The Prognosis of Adult Burkitt's Cell Leukemia in Real-Life Clinical Practice.

Malkan ÜY, Güneş G, Göker H, Haznedaroğlu İC, Acar K, Eliaçık E, Etgül S, Aslan T, Balaban S, Demiroğlu H, Özcebe OI, Sayınalp N, Aksu S, Büyükaşık Y.

Turk J Haematol. 2016 Dec 1;33(4):281-285. doi: 10.4274/tjh.2015.0088. Epub 2016 Apr 18.

41.

Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.

Soyer N, Haznedaroğlu İC, Cömert M, Çekdemir D, Yılmaz M, Ünal A, Çağlıyan G, Bilgir O, İlhan O, Özdemirkıran F, Kaya E, Şahin F, Vural F, Saydam G.

Turk J Haematol. 2017 Mar 1;34(1):27-33. doi: 10.4274/tjh.2016.0005. Epub 2016 Apr 18.

42.

Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case.

Malkan UY, Gunes G, Eliacik E, Haznedaroglu IC.

Int Med Case Rep J. 2016 Mar 16;9:61-4. doi: 10.2147/IMCRJ.S101000. eCollection 2016.

43.

Qualitative/Chemical Analyses of Ankaferd Hemostat and Its Antioxidant Content in Synthetic Gastric Fluids.

Koluman A, Akar N, Malkan UY, Haznedaroglu IC.

Biomed Res Int. 2016;2016:8957820. doi: 10.1155/2016/8957820. Epub 2016 Jan 26.

44.

The factors affecting early death after the initial therapy of acute myeloid leukemia.

Malkan UY, Gunes G, Eliacik E, Haznedaroglu IC, Etgul S, Aslan T, Yayar O, Aydin S, Demiroglu H, Ozcebe OI, Sayinalp N, Goker H, Aksu S, Buyukasik Y.

Int J Clin Exp Med. 2015 Dec 15;8(12):22564-9. eCollection 2015.

45.

Clinicopathological associations of acquired erythroblastopenia.

Gunes G, Malkan UY, Yasar HA, Eliacik E, Haznedaroglu IC, Demiroglu H, Sayinalp N, Aksu S, Etgul S, Aslan T, Goker H, Ozcebe OI, Buyukasik Y.

Int J Clin Exp Med. 2015 Dec 15;8(12):22515-9. eCollection 2015.

46.

Reply: Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib.

Malkan UY, Gunes G, Etgul S, Aslan T, Aydin S, Haznedaroglu IC.

Ann Pharmacother. 2016 Apr;50(4):336. doi: 10.1177/1060028016629981. Epub 2016 Feb 9. No abstract available.

PMID:
26861992
47.

Antibacterial Activities of Ankaferd Hemostat (ABS) on Shiga Toxin-Producing Escherichia coli and Other Pathogens Significant in Foodborne Diseases.

Koluman A, Akar N, Haznedaroğlu İC.

Turk J Haematol. 2017 Mar 1;34(1):93-98. doi: 10.4274/tjh.2015.0073. Epub 2015 Aug 6.

48.

Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems.

Bektaş Ö, Üner A, Eliaçık E, Uz B, Işık A, Etgül S, Bozkurt S, Haznedaroğlu İC, Göker H, Sayınalp N, Aksu S, Demiroğlu H, Özcebe Oİ, Büyükaşık Y.

Turk J Haematol. 2016 Jun 5;33(2):119-26. doi: 10.4274/tjh.2014.0455. Epub 2015 Aug 6.

49.

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms.

Eliaçık E, Işık A, Aksu S, Üner A, Büyükaşık Y, Sayınalp N, Göker H, Özcebe OI, Haznedaroğlu İC.

Turk J Haematol. 2015 Jun;32(2):163-7. doi: 10.4274/tjh.2013.0265. Review.

50.

Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case.

Malkan UY, Gunes G, Eliacik E, Yayar O, Haznedaroglu IC.

Case Rep Hematol. 2015;2015:653178. doi: 10.1155/2015/653178. Epub 2015 Aug 2.

Supplemental Content

Loading ...
Support Center